S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.52 (+0.42%)
AAPL   175.00 (+2.23%)
MSFT   334.90 (+-0.01%)
FB   330.76 (+2.46%)
GOOGL   2,956.95 (+0.39%)
AMZN   3,516.49 (-0.19%)
TSLA   1,067.25 (+1.47%)
NVDA   317.89 (-1.97%)
BABA   125.70 (+0.13%)
NIO   35.07 (+5.89%)
CGC   10.93 (+2.73%)
AMD   144.96 (+0.08%)
GE   98.46 (+0.93%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.45 (+1.75%)
PFE   51.41 (-0.60%)
AMC   32.03 (+3.19%)
ACB   6.57 (+2.98%)
BA   211.04 (+1.06%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.52 (+0.42%)
AAPL   175.00 (+2.23%)
MSFT   334.90 (+-0.01%)
FB   330.76 (+2.46%)
GOOGL   2,956.95 (+0.39%)
AMZN   3,516.49 (-0.19%)
TSLA   1,067.25 (+1.47%)
NVDA   317.89 (-1.97%)
BABA   125.70 (+0.13%)
NIO   35.07 (+5.89%)
CGC   10.93 (+2.73%)
AMD   144.96 (+0.08%)
GE   98.46 (+0.93%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.45 (+1.75%)
PFE   51.41 (-0.60%)
AMC   32.03 (+3.19%)
ACB   6.57 (+2.98%)
BA   211.04 (+1.06%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.52 (+0.42%)
AAPL   175.00 (+2.23%)
MSFT   334.90 (+-0.01%)
FB   330.76 (+2.46%)
GOOGL   2,956.95 (+0.39%)
AMZN   3,516.49 (-0.19%)
TSLA   1,067.25 (+1.47%)
NVDA   317.89 (-1.97%)
BABA   125.70 (+0.13%)
NIO   35.07 (+5.89%)
CGC   10.93 (+2.73%)
AMD   144.96 (+0.08%)
GE   98.46 (+0.93%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.45 (+1.75%)
PFE   51.41 (-0.60%)
AMC   32.03 (+3.19%)
ACB   6.57 (+2.98%)
BA   211.04 (+1.06%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.52 (+0.42%)
AAPL   175.00 (+2.23%)
MSFT   334.90 (+-0.01%)
FB   330.76 (+2.46%)
GOOGL   2,956.95 (+0.39%)
AMZN   3,516.49 (-0.19%)
TSLA   1,067.25 (+1.47%)
NVDA   317.89 (-1.97%)
BABA   125.70 (+0.13%)
NIO   35.07 (+5.89%)
CGC   10.93 (+2.73%)
AMD   144.96 (+0.08%)
GE   98.46 (+0.93%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.45 (+1.75%)
PFE   51.41 (-0.60%)
AMC   32.03 (+3.19%)
ACB   6.57 (+2.98%)
BA   211.04 (+1.06%)
LON:GWP

326553 (GWP.L) Share Forecast, Price & News

Add
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2.32 million shs
Average Volume
956,721 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Receive GWP News and Ratings via Email

Sign-up to receive the latest news and ratings for 326553 (GWP.L) and its competitors with MarketBeat's FREE daily newsletter.


About 326553 (GWP.L)

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












326553 (GWP.L) (LON:GWP) Frequently Asked Questions

Who are 326553 (GWP.L)'s key executives?

326553 (GWP.L)'s management team includes the following people:
  • Geoffrey W. Guy, Executive Chairman of the Board
  • Justin Gover, Chief Executive Officer, Director
  • Adam David George, Chief Financial Officer, Company Secretary, Director
  • Christopher John Tovey, Chief Operating Officer, Executive Director
  • Julian S. Gangolli, Executive Director
  • James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
  • Cabot Brown, Non-Executive Independent Director
  • Thomas Gerard Lynch, Non-Executive Independent Director
  • Catherine J. Mackey Ph.D., Non-Executive Independent Director
  • Alicia Secor, Non-Executive Independent Director

What other stocks do shareholders of 326553 (GWP.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 326553 (GWP.L) investors own include GW Pharmaceuticals (GWPH), (CGC), Aurora Cannabis (ACB), Alibaba Group (BABA), Cara Therapeutics (CARA), Cronos Group (CRON), Immunomedics (IMMU), Ceragon Networks (CRNT), Nokia (NOK) and NVIDIA (NVDA).

What is 326553 (GWP.L)'s stock symbol?

326553 (GWP.L) trades on the London Stock Exchange (LON) under the ticker symbol "GWP."

How do I buy shares of 326553 (GWP.L)?

Shares of GWP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is 326553 (GWP.L)'s official website?

The official website for 326553 (GWP.L) is www.gwpharm.com.

Where are 326553 (GWP.L)'s headquarters?

How can I contact 326553 (GWP.L)?

326553 (GWP.L)'s mailing address is Sovereign House, Vision Park, CAMBRIDGE, 00000, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1223-266800.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.